|
Jul 23
|
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
|
|
Jul 22
|
Asian Growth Companies With Strong Insider Ownership In July 2025
|
|
Jul 22
|
High Growth Tech Stocks in Asia for July 2025
|
|
Jul 21
|
Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement
|
|
Jul 14
|
Ascentage Pharma’s Novel Cancer Drug Approved in China
|
|
Jul 14
|
Ascentage Pharma Announces Pricing of Top-Up Placement
|
|
Jul 14
|
Ascentage Pharma Announces Proposed Top-Up Placement
|
|
Jul 10
|
Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug
|
|
Jul 10
|
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
|
|
Jul 8
|
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
|
|
Apr 21
|
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
|
|
Dec 27
|
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
|